ipopba / iStock via Getty Images Quick Read FHLC charges just 0.084% in fees but carries 13% concentration in Eli Lilly. The fund gained 17.9% over one year but returned only 154% over ten years versus the S&P 500’s 235%. Enhanced ACA premium tax credits face 87.5% probability of expiring by January 31 2026. Have You read The New Report Shaking Up Retirement Plans? Americans are answering three questions and many are realizing they can retire earlier than expected. Healthcare investing offers ...

Core Insights - Healthcare investing is characterized by defensive traits during market volatility, but regulatory and political risks can lead to abrupt selloffs [1] - Fidelity MSCI Health Care Index ETF (FHLC) offers a low-cost entry point for investors seeking exposure to the healthcare sector without selecting individual stocks [1] Fund Overview - FHLC tracks the MSCI USA IMI Health Care Index, providing exposure to U.S. healthcare companies across various segments including pharmaceuticals, biotechnology, medical devices, and health insurance [2] - The fund has an expense ratio of 0.084% and includes over 80 holdings, focusing on capital appreciation and modest dividend income [2] Concentration Risk - Eli Lilly constitutes over 13% of FHLC's portfolio, linking its performance closely to GLP-1 obesity drugs, which have seen a 46% increase in stock price over the past year [3] - The top five holdings also include UnitedHealth, Johnson & Johnson, Merck, and AbbVie [3] Performance Analysis - FHLC has shown strong short-term performance, gaining 5.3% in the last month and 17.9% over the past year, outperforming the S&P 500 [4] - However, over five years, FHLC returned 42.6%, significantly lagging behind the S&P 500's 84.5% return, with a widening gap over ten years (154% vs. 235%) [4] Sector Challenges - The underperformance of FHLC reflects broader challenges in the healthcare sector, including drug pricing pressures and slower innovation cycles outside oncology and rare diseases [5] - Recent momentum may indicate potential sector rotation, but investing after outperformance carries inherent risks [5] Policy and Income Considerations - Investors face political and regulatory uncertainties, with an 87.5% probability that enhanced ACA premium tax credits will expire by January 2026, impacting health insurers like UnitedHealth [7] - FHLC's yield of 1.33% is considered modest compared to other market alternatives, with dividend growth of approximately 4.6% annually over five years, barely keeping pace with inflation [8] Suitability for Investors - Growth-focused investors seeking maximum capital appreciation may find FHLC unsuitable due to its long-term underperformance [9] - Retirees prioritizing income generation may also find better yield opportunities in other sectors without sacrificing stability [9] Alternative Options - Vanguard Health Care ETF (VHT) is presented as an alternative, with a slightly higher expense ratio of 0.09%, larger asset base of $20.4 billion, and a higher dividend yield of 1.38% [11] - VHT's longer track record since 2004 and superior liquidity may provide additional confidence for long-term investors [11] Tactical Allocation - FHLC may serve as a tactical allocation for investors seeking low-cost exposure to the healthcare sector, but concentration risk and historical underperformance necessitate careful position sizing [12]

欲览更多环球财经资讯，请移步7×24小时实时财经新闻 市场 1月10日收盘：道指与标普指数创历史新高 三大指数本周均录得涨幅 1月10日美股成交额前20：英特尔本周上涨逾15% 1月10日热门中概股多数下跌 台积电涨1.77%，阿里巴巴跌2.27% 油价周五收高 市场评估伊朗抗议与委内瑞拉石油交易 现货黄金涨0.68%，报4507.52美元/盎司 欧洲股市再创纪录新高 科技股领涨 "美联储传声筒"：特朗普"抢跑"非农数据 白宫承认特朗普"非故意"泄露就业数据，正在审查发布流程 美方称在加勒比海扣押"奥利娜"号油轮 特朗普：美国将决定哪些公司可以进入委内瑞拉 石油公司将投1千亿美元 特朗普：今天被扣押的油轮正返回委内瑞拉 特朗普：美国将立即开始提炼和销售5000万桶委石油 对委军事行动后 美方工作组首次进入委内瑞拉 委内瑞拉称与美国启动"探索性外交"进程 宏观 特朗普关税案悬而未决 美国最高法院下周三将再表法律意见 特朗普：今天与石油企业会晤的主要话题将是委内瑞拉 美内政部长称委内瑞拉石油开发不靠美国政府出资 美国国务卿鲁比奥：委内瑞拉目前处于"稳定阶段" 美国商务部长据悉会晤主要建商 推动降低购房成本 202 ...

Key Points AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers. 10 stocks we like better than AbbVie › The technology sector is an excellent place to find high-growth stocks with promising prospects. However, it is a cyclical sector that doesn't perform as well when the economy tanks. It's critical for investors to diversify their tech holdings, perhaps by putting their money into more defensive industries that behave differently during dow ...

Key Takeaways JNJ agreed to match U.S. drug prices under Trump's MFN plan and received a tariff exemption.JNJ is advancing a $55B plan to expand U.S. manufacturing, research and technology by early 2029.JNJ is building new U.S. facilities in Pennsylvania and North Carolina, including a $2B biologics plant.Johnson & Johnson (JNJ) recently signed a landmark agreement with the Trump administration to lower drug prices in the United States.Following this deal, JNJ joins several other large-cap pharma companies ...

强生（JNJ）周五早盘下跌0.5%，该公司同意降低某些药品价格并加入TrumpRx.gov平台，以换取关税 豁免和美国投资计划，但专家认为对大多数参保患者的节省有限。 责任编辑：张俊 SF065 强生（JNJ）周五早盘下跌0.5%，该公司同意降低某些药品价格并加入TrumpRx.gov平台，以换取关税 豁免和美国投资计划，但专家认为对大多数参保患者的节省有限。 责任编辑：张俊 SF065 ...

1. 1月9日(周五)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨004%，标普500指数期货涨0.11%，纳指期货涨0.20%。 | ■ US 30 | 49,283.30 | 49,354.80 | 49,215.70 | +17.60 | +0.04% | | --- | --- | --- | --- | --- | --- | | ■ US 500 | 6,929.00 | 6,932.30 | 6,913.00 | +7.60 | +0.11% | | ■ US Tech 100 | 25,559.30 | 25,585.70 | 25,446.70 | +52.20 | +0.20% | 2. 截至发稿，德国DAX指数涨0.41%，英国富时100指数涨0.52%，法国CAC40指数涨0.86%，欧洲斯托克50指数涨1.06%。 | I 德国DAX30 | 25,228.32 | 25,269.21 | 25,106.61 | +102.41 | +0.41% | | --- | --- | --- | --- | --- | --- | | 器 英国富时100 | 10,097.20 | ...

有统计数显示，美国患者们目前为处方药所支付的整体费用远高于其他发达国家，往往接近其他国家销 售价格的三倍。特朗普政府一直在施压制药商们把美国国内药价降至海外所支付的水平。 "这份联合协议满足了特朗普总统向美国制药行业提出的要求，并为公司的制药产品提供关税豁免，"强 生周四在一份声明中表示。不过双方协议的具体条款未予以披露，包括下调后的药价细节或涵盖哪些药 品。 美国制药巨头强生公司(JNJ.US)当地时间周四表示，已经与美国总统唐纳德·特朗普政府达成协议，将为 美国民众们下调药品价格，以换取获得特朗普政府至关重要的关税豁免。 据了解，在与强生达成协议之前，特朗普政府于2025年12月与另外九家美国大型制药公司达成协议，要 求它们下调面向联邦政府医疗补助计划(Medicaid)以及现金自费消费者们的药品价格，旨在使美国药品 成本与其他富裕发达国家的销售水平接轨。 强生表示，将参与特朗普政府推出的TrumpRx.gov网站，使美国人能够以大幅折扣价格购买其所需要的 强生公司药品。该公司还将以与其他发达国家相当的价格向Medicaid提供关键药品获取渠道。 根据12月达成的一项重磅协议，所有九家美国制药商同意下调其 ...

强生表示，将参与特朗普政府推出的TrumpRx.gov网站，使美国人能够以大幅折扣价格购买其所需要的 强生公司药品。该公司还将以与其他发达国家相当的价格向Medicaid提供关键药品获取渠道。 （原标题：?强生(JNJ.US)加入美国药品降价联盟 换取特朗普关税豁免） 智通财经APP获悉，美国制药巨头强生公司(JNJ.US)当地时间周四表示，已经与美国总统唐纳德·特朗普 政府达成协议，将为美国民众们下调药品价格，以换取获得特朗普政府至关重要的关税豁免。 据了解，在与强生达成协议之前，特朗普政府于2025年12月与另外九家美国大型制药公司达成协议，要 求它们下调面向联邦政府医疗补助计划(Medicaid)以及现金自费消费者们的药品价格，旨在使美国药品 成本与其他富裕发达国家的销售水平接轨。 有统计数显示，美国患者们目前为处方药所支付的整体费用远高于其他发达国家，往往接近其他国家销 售价格的三倍。特朗普政府一直在施压制药商们把美国国内药价降至海外所支付的水平。 "这份联合协议满足了特朗普总统向美国制药行业提出的要求，并为公司的制药产品提供关税豁免，"强 生周四在一份声明中表示。不过双方协议的具体条款未予以披露，包 ...

Group 1 - The Trump administration has reached a deal with Johnson & Johnson to lower the prices of certain medications, aiming to enhance affordability for consumers [1] - The agreement is part of a broader initiative to address prescription drug costs, which have been a significant concern for many Americans [1] - Johnson & Johnson is expected to implement price reductions on specific drugs, although the exact medications and the extent of the price cuts have not been detailed [1] Group 2 - This deal reflects ongoing efforts by the government to negotiate better pricing with pharmaceutical companies, which may influence future pricing strategies across the industry [1] - The collaboration with Johnson & Johnson could set a precedent for similar agreements with other pharmaceutical companies, potentially reshaping the competitive landscape [1] - The administration's focus on drug pricing is likely to impact public perception and trust in pharmaceutical companies, as affordability becomes a key issue for consumers [1]